November 20, 2026 · BMC women's health · DOI: 10.1186/s12905-026-04809-0

HDAC2/Parkin axis regulates mitochondrial dysfunction and mitophagy in polyendocrine metabolic ovarian syndrome.

Listen to this summary

This study asks whether the HDAC2/Parkin axis drives DHT-induced mitochondrial dysfunction and impaired mitophagy in granulosa cells, and whether HDAC inhibition could serve as a therapy for polycystic ovary-like metabolic disease (PMOS). In KGN granulosa cells, HDAC2 knockdown reversed DHT-induced mitochondrial damage, whereas Parkin knockdown abolished this protection, and HDAC2 was found to bind Parkin and affect its acetylation. In a DHEA plus high-fat diet rat model, the HDAC inhibitor SAHA improved estrous cycles, hormone and insulin resistance markers, ovarian morphology, and PINK1/Parkin-mediated mitophagy, supporting HDAC2/Parkin as a potential therapeutic target.

Mingqin Shi, Jianlei Zhong, Rong Zhao, Xiaojuan Zhang, Jing Wang, Xiaoyan Xia, Xiaoqi Wang, Xi Li, Qiong Zhang, Yang Chen

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play